Skip to content
Homepage
Author:
XVIVO Perfusion AB
Posted Date:
June 26, 2026
Conference call on Interim Report April-June 2026
XVIVO Perfusion AB
June 26, 2026
Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO’s Heart Technology
XVIVO Perfusion AB
May 18, 2026
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
XVIVO Perfusion AB
April 27, 2026
Interim Report January – March 2026
XVIVO Perfusion AB
April 24, 2026
XVIVO Presents Encouraging Results From First Clinical Trial Using Hypothermic Oxygenated Perfusion (HOPE) In Direct Procurement DCD Heart Transplantation
XVIVO Perfusion AB
April 22, 2026
Preliminary One-Year Follow-up Data From the US Preserve Trial for XVIVO’s Heart Technology Presented at ISHLT in Toronto
XVIVO Perfusion AB
April 22, 2026
Conference Call on Interim Report January-March 2026
XVIVO Perfusion AB
April 17, 2026
The 12-Month Follow-up Results from XVIVO’s European Multicenter Heart Trial is Now Published in the European Heart Journal
XVIVO Perfusion AB
April 16, 2026
Annual Report 2025
XVIVO Perfusion AB
April 1, 2026
Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ)
XVIVO Perfusion AB
March 19, 2026
1
2
Next
